EMA Confirms Recommendation Of Synchron Suspensions
But Finds Alternative Data To Support Marketing Authorizations For Eight Medicines
Following a review of an earlier decision, the European Medicines Agency has confirmed its recommendation to suspend marketing authorizations for dozens of medicines with bioequivalence studies conducted by Synchron Research Services. However, eight products have been spared after alternative supporting data was identified.
You may also be interested in...
With multiple Humira biosimilars slated for launch in the US next year, some simultaneously, a Vizient survey provides some insights into what could be the most important differentiating aspects. Generics Bulletin speaks to Steven Lucio, Vizient senior principal of pharmacy solutions, about the findings.
Italian API and CDMO specialist Olon is expanding its high-potency capabilities at a site in India, at the same time as unveiling plans to invest a further €30m in a domestic biotech hub.
SK Capital announced agreement to acquire Apotex, saying it will invest to “support Apotex’s next phase of growth and continued innovation for patient affordability."